Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
LA JOLLA, Calif., July 29, 2013 (GLOBE NEWSWIRE) -- Innovus Pharmaceuticals, Inc., ("Innovus Pharma") www.innovuspharma.com (OTCBB:INNV) announced today it has entered into a non-exclusive co-promotion agreement with Consortia Health Clinical Continence Services, LLC ("Consortia"). Under the agreement, Consortia will market Innovus Pharma's product for premature ejaculation, EjectDelay, in the states of the United States, where Consortia has commercial reach and presence. Consortia will target urologists and sex therapists in its co-promotion efforts and Innovus Pharma will pay Consortia a co-promotion fee based on a percentage of the net sales of EjectDelay to Consortia's targeted physicians and their patients.
Help employers find you! Check out all the jobs and post your resume.
LA JOLLA, Calif., July 29, 2013 (GLOBE NEWSWIRE) -- Innovus Pharmaceuticals, Inc., ("Innovus Pharma") www.innovuspharma.com (OTCBB:INNV) announced today it has entered into a non-exclusive co-promotion agreement with Consortia Health Clinical Continence Services, LLC ("Consortia"). Under the agreement, Consortia will market Innovus Pharma's product for premature ejaculation, EjectDelay, in the states of the United States, where Consortia has commercial reach and presence. Consortia will target urologists and sex therapists in its co-promotion efforts and Innovus Pharma will pay Consortia a co-promotion fee based on a percentage of the net sales of EjectDelay to Consortia's targeted physicians and their patients.
Help employers find you! Check out all the jobs and post your resume.
